RO7303359
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy
Trial Timeline
Dec 8, 2020 → Jan 4, 2023
NCT ID
NCT04615325About RO7303359
RO7303359 is a phase 1 stage product being developed by Roche for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT04615325. Target conditions include Geographic Atrophy.
What happened to similar drugs?
1 of 12 similar drugs in Geographic Atrophy were approved
Approved (1) Terminated (3) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04615325 | Phase 1 | Completed |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 40 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 38 |
| avacincaptad pegol | Astellas Pharma | Approved | 50 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 33 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 40 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 39 |
| FWY003 + Placebo | Novartis | Phase 2 | 42 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 35 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 35 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 36 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 39 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 36 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 24 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 41 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 24 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 34 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 34 |